IDH2 and acute myeloid leukemia: Therefore, the purpose of this study was (1) to determine whether an acquired driver mutation in IDH1 or IDH2 predisposes AML patients toward cardiac dysfunction or even triggers myocardial susceptibility to antineoplastic treatments with cardiotoxic agents (such as anthracyclines), and (2) to integrate the novel findings from this translational retrospective study into the clinical context of cardio-oncology as a novel and rapidly growing research area.